{"url":"https://lda.senate.gov/api/v1/filings/c19e01c9-a3a3-4339-bbd3-dcca8fe4604c/","filing_uuid":"c19e01c9-a3a3-4339-bbd3-dcca8fe4604c","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2013,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/c19e01c9-a3a3-4339-bbd3-dcca8fe4604c/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Henry W Menn III - Principal","dt_posted":"2014-01-16T10:23:09.307000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 13th Street, NW","registrant_address_2":"6th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":287895,"url":"https://lda.senate.gov/api/v1/registrants/287895/","house_registrant_id":37058,"name":"BROWN RUDNICK LLP","description":"Law Firm","address_1":"601 13th Street, NW","address_2":"6th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANDREW P. STREHLE","contact_telephone":"","dt_updated":"2022-04-06T16:06:44.387651-04:00"},"client":{"id":177009,"url":"https://lda.senate.gov/api/v1/clients/177009/","client_id":1005002,"name":"HOSPIRA, INC.","general_description":"Device and drug manufacturer","client_government_entity":false,"client_self_select":false,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-01-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":4627,"prefix":null,"prefix_display":null,"first_name":"HENRY","nickname":null,"middle_name":"W","last_name":"MENN","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false},{"lobbyist":{"id":59329,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"BOWLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":46715,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"LAYMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues relating to generic drug labeling; S. 959:  The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":4627,"prefix":null,"prefix_display":null,"first_name":"HENRY","nickname":null,"middle_name":"W","last_name":"MENN","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false},{"lobbyist":{"id":59329,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"BOWLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":46715,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"LAYMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues relating to drug and nutrient shortages; P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 232: Medical Device Access and Innovation Protection Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":4627,"prefix":null,"prefix_display":null,"first_name":"HENRY","nickname":null,"middle_name":"W","last_name":"MENN","suffix":"iii","suffix_display":"III"},"covered_position":"Min SD & Counsel, Cmte on Vet Affairs (04)","new":false},{"lobbyist":{"id":46715,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"LAYMAN","suffix":null,"suffix_display":null},"covered_position":"SPA, Sen Stabenow(05-07)","new":false},{"lobbyist":{"id":59329,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"BOWLIN","suffix":null,"suffix_display":null},"covered_position":"Secr for Congr & Intgv Affairs, Dept. Labor 01-02","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}